Open access
Aug 2026
Histone deacetylase activity limits the response to EZH2 inhibition-based therapy in epithelioid sarcoma and is targetable by epigenetic combination
N. Arrighetti, C. Soffientini, V. Zuco et al.
· bioRxiv · 0 citations